Trial Profile
The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Mitumomab (Primary)
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SILVA
- 10 Sep 2005 New trial record.